Products
China Recombinant Hepatitis B Vaccine With Enhanced Immune Response Manufacturer, Supplier, Factory
AIM Honesty Biopharmaceutical Co., Ltd. is a professional China manufacturer providing Recombinant Hepatitis B Vaccine With Enhanced Immune Response. Based on advanced recombinant Hansenula polymorpha expression technology and patented adjuvant technology, the product is designed to support stronger immune stimulation and reliable hepatitis B prevention solutions. The RECVAX® series has been applied for 20 years with nearly 500 million doses used.
Recombinant Hepatitis B Vaccine With Enhanced Immune Response is developed and manufactured by AIM Honesty Biopharmaceutical Co., Ltd., a professional vaccine manufacturer specializing in biological product research, development, and production. The product is based on a recombinant Hansenula polymorpha expression technology platform and patented adjuvant technology, providing healthcare organizations and professional buyers with a vaccine solution focused on immune response performance and long-term immunization needs.
When selecting a hepatitis B vaccine supplier, medical institutions and distributors usually pay attention to more than product availability. Manufacturing experience, technical platform, quality management capability, and practical application history are important factors that influence procurement decisions. AIM Honesty Biopharmaceutical Co., Ltd. combines advanced biological technology with established production experience to support professional vaccine supply requirements.
The RECVAX® series independently developed by AIM Honesty Biopharmaceutical Co., Ltd. adopts the first domestic and internationally leading recombinant Hansenula polymorpha expression technology platform together with patented adjuvant technology. Through continuous technology development and manufacturing improvement, the company provides hepatitis B immunization products supported by long-term market application experience.
Immune Response Needs
For hepatitis B vaccine procurement, immune response performance is one of the important evaluation factors. A vaccine solution should not only meet basic immunization requirements but also provide technical support for effective antigen stimulation and long-term immune protection.
The development concept of this product focuses on improving immune response through advanced expression technology and adjuvant design. By combining recombinant Hansenula polymorpha technology with patented adjuvant technology, AIM Honesty Biopharmaceutical Co., Ltd. provides a solution designed around enhanced immunogenicity requirements.
The following factors are commonly considered when evaluating vaccine immune response performance:
1. Antigen presentation capability: Effective antigen presentation plays an important role in stimulating immune system recognition.
2. Technology platform stability: A mature production platform helps maintain consistent product characteristics.
3. Long-term application experience: Real-world market use provides valuable reference for product evaluation.
Technology Platform
Hansenula Polymorpha Expression Technology
The production technology platform is one of the key differences between vaccine products. Recombinant yeast expression systems provide an advanced approach for hepatitis B vaccine manufacturing by supporting controlled biological production processes.
The Hansenula polymorpha expression technology used in RECVAX® represents an advanced recombinant production route. Compared with traditional technical approaches, this platform helps support product purity management and manufacturing consistency.
Patented Adjuvant Technology
AIM Honesty Biopharmaceutical Co., Ltd. applies patented adjuvant technology based on in situ adsorption technology. After administration, this technology creates an "antigen bank" in the body, allowing sustained antigen release and extending antigen action time.
This mechanism helps enhance stimulation of immune response and improve immunogenicity, providing technical support for hepatitis B immunization programs requiring reliable immune response performance.
Product Development Value
The value of a vaccine product depends on the combination of technology, manufacturing capability, and application experience. For professional buyers, understanding the background behind product development helps evaluate whether a supplier can provide stable long-term cooperation.
AIM Honesty Biopharmaceutical Co., Ltd. has focused on hepatitis B vaccine development and manufacturing. The RECVAX® series has been available on the market for 20 years, covering 31 provinces, cities, and autonomous regions in China, with total market usage of nearly 500 million doses.
Immune Performance Data
Long-term immune response evaluation provides important information for understanding vaccine performance. A study led by Academician Li Lanjuan evaluated booster immunization among children aged 5 to 15 years using four different hepatitis B vaccines.
After a 0-1-6-month booster series with 10 μg RECVAX® (Hansenula-yeast) vaccine, the anti-HBs seropositive rates at 1, 5, and 8 years after booster immunization reached 83.4%, which was the highest among the four evaluated vaccines.
This research provides supporting information regarding immune response characteristics and long-term antibody maintenance of the Hansenula yeast vaccine technology route.
Product Specification
Product specifications and quality indicators are important references for healthcare organizations and distributors when evaluating vaccine suppliers. AIM Honesty Biopharmaceutical Co., Ltd. follows strict pharmacopeia standards during production, focusing on key quality control indicators to maintain product consistency.
The following table presents the comparison of important quality-related items among different production systems.
| Pharmacopoeia Item | Endotoxin content | Free formaldehyde | Thiocyanate | Residual amount of antibiotics | Residual amount of bovine serum albumin |
| Hansenula polymorpha | Less than 5 EU/ml | Less than 15 µg/ml | Not applicable | Not applicable | Not applicable |
| Saccharomyces cerevisiae | Less than 5 EU/ml | Less than 20 µg/ml | Should be less than 1 µg/ml | Not applicable | Not applicable |
| CHO cells | Less than 10 EU/ml | Less than 50 µg/ml | Not applicable | No more than 50 ng/dose | No more than 50 ng/dose |
Production Route Comparison
Different manufacturing routes may influence production characteristics, quality control requirements, and product development strategies. Understanding these differences helps procurement teams make more informed evaluations when selecting vaccine solutions.
| Process | Hansenula Yeast | Saccharomyces Yeast | CHO Cell |
| Process Description | Most advanced process | First generation yeast expression system | Most dated process |
| Tumorigenic Risk? | No | No | Yes |
| Antibiotic Added? | No | No | Yes |
| Bovine Serum Albumin Added? | No | No | Yes |
| Animal Pathogen Risk? | No | No | Yes |
| Thiocyanate Added? | No | Yes | No |
| Immunogenicity | High | Higher | Not much (general double dose vs. yeast shows poor response) |
| Vaccine Purity | Highest | Higher | More additives, lower purity |
| Potential Benefit | Strongest cellular immunity induction | Second strongest cellular immunity induction | Weakest cellular immunity induction |
| Representative Product Statement | 10 µg applicable to all populations | 10 µg applicable only to children | 10 µg immunogenicity poor, almost discontinued |
Procurement Evaluation
For vaccine distributors and healthcare organizations, choosing a supplier requires a comprehensive evaluation rather than focusing on a single factor. The following aspects can help buyers understand the value of a professional vaccine manufacturer.
| Evaluation Factor | Buyer Consideration |
| Technology Platform | Advanced recombinant expression technology and stable manufacturing process capability |
| Production Experience | Long-term market application experience and established biological product manufacturing background |
| Quality Management | Monitoring of important product indicators and compliance with pharmacopeia requirements |
| Application Support | Professional communication and technical information support for healthcare partners |
Application Groups
Different populations have different hepatitis B prevention requirements. Understanding application scenarios helps healthcare organizations select suitable immunization solutions according to their service responsibilities.
| Application Group | Usage Consideration |
| Newborns | Especially important for newborns whose mothers are HBsAg and HBeAg positive |
| Healthcare Workers | Individuals with potential blood exposure risks in medical environments |
| Laboratory Personnel | Professionals working with biological samples and medical testing environments |
Enhanced Immune Mechanism
The immune response performance of a Recombinant Hepatitis B Vaccine With Enhanced Immune Response depends on multiple factors, including antigen characteristics, production technology, and adjuvant design. AIM Honesty Biopharmaceutical Co., Ltd. combines recombinant Hansenula polymorpha expression technology with patented adjuvant technology to provide technical support for improved immune stimulation.
The patented adjuvant technology used in RECVAX® applies in situ adsorption technology. After administration, the system forms an "antigen bank" in the body, which helps maintain antigen release and extend antigen action duration.
This technical design supports continuous stimulation of immune response and improves immunogenicity, helping meet the requirements of populations requiring reliable hepatitis B immunization solutions.
Manufacturing Process
Professional manufacturing capability is a key factor for biological product suppliers. Vaccine production requires careful management of multiple stages, including technology application, production control, quality evaluation, and process management.
| Production Stage | Main Focus |
| Technology Development | Continuous improvement based on recombinant Hansenula polymorpha expression technology platform |
| Manufacturing Control | Professional production procedures and process management |
| Quality Evaluation | Monitoring of important quality-related indicators according to pharmacopeia requirements |
| Product Supply | Supporting healthcare organizations with stable vaccine product cooperation |
Production Capability
AIM Honesty Biopharmaceutical Co., Ltd. focuses on vaccine research, development, and manufacturing. Modern production workshops and professional technical teams provide the foundation for maintaining consistent product quality and supporting long-term market supply.
Professional production environments are essential for biological products because manufacturing quality depends on effective process management, equipment operation, and technical experience.
The company's manufacturing capability supports the continuous development and supply of hepatitis B vaccine products while maintaining attention to quality and production reliability.
Quality Control System
Quality management is an important part of vaccine manufacturing. AIM Honesty Biopharmaceutical Co., Ltd. focuses on product consistency through professional production management and quality evaluation procedures.
Key quality management considerations include:
1. Raw material and production process management: maintaining controlled manufacturing procedures throughout production.
2. Product quality evaluation: monitoring important indicators related to product requirements.
3. Technology consistency: applying established recombinant production technology to support stable product characteristics.
| Quality Focus | Importance For Buyers |
| Process Control | Helps maintain consistency during vaccine manufacturing |
| Quality Indicators | Provides reference information for product evaluation |
| Manufacturing Experience | Supports reliable long-term cooperation with professional partners |
Market Application Experience
Long-term application experience is an important reference when healthcare organizations evaluate vaccine suppliers. According to the information provided by AIM Honesty Biopharmaceutical Co., Ltd., the RECVAX® series has been available on the market for 20 years.
The product has covered 31 provinces, cities, and autonomous regions in China, with total market usage of nearly 500 million doses. This application history reflects the company's continuous involvement in hepatitis B prevention and biological product manufacturing.
Professional Cooperation
For hospitals, medical distributors, and healthcare organizations, reliable cooperation requires transparent communication, professional product support, and stable manufacturing capability.
AIM Honesty Biopharmaceutical Co., Ltd. provides professional cooperation support based on its vaccine development experience and manufacturing background. The company focuses on helping partners understand product information, technology characteristics, and application value.
Frequently Asked Questions
Q: What is the main purpose of this vaccine product?
A: This product is designed for hepatitis B immunization needs and provides a vaccine solution developed for preventing hepatitis B virus infection. It is suitable for individuals requiring hepatitis B prevention according to professional vaccination programs and healthcare requirements.
Q: What technology is used in the manufacturing process?
A: The Recombinant Hepatitis B Vaccine With Enhanced Immune Response is developed using recombinant Hansenula polymorpha expression technology. AIM Honesty Biopharmaceutical Co., Ltd. independently developed the RECVAX® series based on an advanced recombinant Hansenula polymorpha expression technology platform combined with patented adjuvant technology.
Q: How does the adjuvant technology support immune response?
A: The patented adjuvant technology uses in situ adsorption technology to create an antigen bank after administration. This design helps maintain antigen release duration, extend antigen action time, and enhance stimulation of immune response.
Q: What factors should buyers evaluate before selecting a hepatitis B vaccine supplier?
A: Professional buyers usually consider several aspects, including manufacturing experience, technology platform, product quality management, application history, and supplier communication capability. These factors help organizations establish stable and reliable cooperation.
Q: How long has the RECVAX® series been applied in the market?
A: According to the provided company information, the RECVAX® series has been available on the market for 20 years. The product has covered 31 provinces, cities, and autonomous regions in China, with total market usage of nearly 500 million doses.
Q: Which groups may require hepatitis B immunization?
A: According to the provided product information, important application groups include newborns, especially those whose mothers are HBsAg and HBeAg positive, as well as healthcare workers and laboratory personnel who may have blood exposure risks.
Q: What quality information is available for product evaluation?
A: Product evaluation includes important indicators such as endotoxin content, free formaldehyde level, residual substances, and other pharmacopeia-related requirements. These quality indicators provide reference information for professional product assessment.
Q: Why is manufacturing experience important for vaccine procurement?
A: Vaccine products require strict manufacturing management and stable production capability. A supplier with long-term development and application experience can provide stronger support for product evaluation, communication, and cooperation.
Q: Does AIM Honesty Biopharmaceutical Co., Ltd. provide cooperation support for medical organizations?
A: AIM Honesty Biopharmaceutical Co., Ltd. focuses on vaccine research, development, and manufacturing. The company provides professional product communication and technical information support for healthcare partners evaluating vaccine solutions.
Conclusion
Selecting a hepatitis B vaccine requires comprehensive consideration of technology platform, manufacturing experience, quality management, and practical application value. AIM Honesty Biopharmaceutical Co., Ltd. combines recombinant technology with patented adjuvant technology to provide a vaccine solution focused on immune response performance and long-term hepatitis B prevention needs.
With 20 years of market application experience and nearly 500 million doses used, the RECVAX® series demonstrates the company's continuous commitment to vaccine innovation and biological product manufacturing. For healthcare institutions, distributors, and professional procurement partners, Recombinant Hepatitis B Vaccine With Enhanced Immune Response provides a reliable solution supported by established technology and manufacturing expertise.
Related Products
Hot Products
A-Type Meningitis Vaccine
To better prevent meningococcal meningitis, you can choose AIM Persistence Biopharmaceutical Co., Ltd. as your A-Type Meningitis Vaccine manufacturer. We have our own brand, and our vaccines offer strong protection, not only effectively preventing A-type meningococcal meningitis but also providing protection against other serotypes.
Hepatitis A and B Vaccines
AIM Honesty Biopharmaceutical Co., Ltd. is a reliable manufacturer. Our independently developed Hepatitis A and B vaccines utilize advanced technology, offering strong immune effects and providing long-lasting protection. They have demonstrated excellent results in comparisons with many imported products of the same dosage and various domestic products with different dosages.
Meningitis Preventive Vaccine
AIM Persistence Biopharmaceutical Co., Ltd. is a professional manufacturer of Meningitis Preventive Vaccines. Vaccination with this safe and effective vaccine can prevent acute infectious diseases caused by Neisseria meningitidis, providing reliable protection, which is especially important during the high-incidence seasons of spring and winter.
Bacterial Meningitis Vaccine
You can confidently choose AIM Persistence Biopharmaceutical Co., Ltd. as your Bacterial Meningitis Vaccine manufacturer and supplier. Our vaccines have achieved high coverage and recognition in China and provide a reliable option for international partners, offering precise prevention against the four most prevalent serotypes of meningococcal meningitis.
Human Diploid Hepatitis A Vaccine
If you are looking for a manufacturer that can provide a stable, long-term supply of Human Diploid Hepatitis A Vaccine, you can choose AIM Action Biopharmaceutical Co., Ltd. from China. We produce vaccines using internationally recognized safe human diploid cells (KMB17) as the culture medium, eliminating the potential risk of viral contamination and tumorigenicity associated with animal-derived cells, resulting in a purer and safer product.
Inactivated Hepatitis A Vaccine
AIM Action Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of AIM Vaccine Co., Ltd., is a reliable supplier with Inactivated Hepatitis A Vaccine as its core product. We utilize classic inactivation technology to completely eliminate the virus's replication ability while retaining its immunogenicity, thus fundamentally preventing the risk of infection caused by vaccination.
- Related Blog
- Reviews
